Tepezza (teprotumumab) has emerged as a groundbreaking treatment for thyroid eye disease, offering hope to patients with this rare condition. Approved by the FDA in January 2020, Tepezza has shown […]
Understanding and Managing Adverse Events in Patients Treated with Tepezza Read More »
The U.S. Food and Drug Administration (FDA) recently took a significant step toward enhancing patient safety by updating the warning label for Horizon Pharmaceutical’s drug, Tepezza. Tepezza is a medication
Tepezza: FDA Adds Hearing Loss and Impairment Warnings to Drug Label Read More »
Did You Have Hearing Problems After Tepezza® Injections? A study shows 16% of patients taking Horizon Therapeutics’ thyroid eye disease drug Tepezza may experience long-term otologic symptoms like hearing loss
